ArticleScientific reports2021
Development of comorbidities in type 2 diabetes between 2005 and 2017 using German claims data.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Socioeconomic Inequalities and Type 2 Diabetes Comorbidities: A Systematic Review and Meta-Analysis on Observational Studies.Endocrinology, diabetes & metabolism · 2026Pooled it
- Global prevalence of multimorbidity among people living with type 2 diabetes: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.Diabetes, obesity & metabolism · 2026Trial
- Article
- Association of Elevated Galectin-4 Concentrations with Obesity, Diabetes, and Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Comorbidity Prevalence in Prediabetes and Type 2 Diabetes: A Cross-Sectional Study in a Predominantly Hispanic U.S.-Mexico Border Population.International journal of environmental research and public health · 2025Article
- Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Physical working conditions over time: a repeated cross-sectional study in German employees.Journal of occupational medicine and toxicology (London, England) · 2024Article
- Type 2 diabetes in the employed population: do rates and trends differ among nine occupational sectors? An analysis using German health insurance claims data.BMC public health · 2024Article
- Type 2 diabetes severity in the workforce: An occupational sector analysis using German claims data.PloS one · 2024Article
- Article
- Socioeconomic inequalities in type 2 diabetes comorbidities in different population subgroups: trend analyses using German health insurance data.Scientific reports · 2023Article
- Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017-A German Longitudinal Study Based on Claims Data.International journal of environmental research and public health · 2023Article
- Health-Related Quality of Life and Healthcare Events in Patients with Monotherapy of Anti-Diabetes Medications.Healthcare (Basel, Switzerland) · 2023Article
- COVID-19 fear and its associated correlates among type-2 diabetes patients in Bangladesh: A hospital-based study.Global mental health (Cambridge, England) · 2023Article
- Compression and Expansion of Morbidity—Secular Trends Among Cohorts of the Same AgeDeutsches Arzteblatt international · 2022Review
- Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence.EClinicalMedicine · 2022Article
- Early Referral to Nephrological Care and the Uptake of Peritoneal Dialysis. An Analysis of German Claims Data.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Against the background of increasing life expectancy over time, several hypotheses have been proposed on the way morbidity has been developing. In type 2 diabetes (T2D), previous research suggests that morbidity compression could be ruled out due to increasing prevalence and life expectancy with T2D over time. Understanding how the health state in individuals with T2D is developing would help identify whether morbidity expansion or a dynamic equilibrium pattern applies for this disease. This study aims to answer the following questions: (1) How do the number and the prevalence of T2D concordant comorbidities develop over time? (2) What does this imply in terms of morbidity development in T2D in Germany? The study used claims data from a statutory health insurance provider in Lower Saxony, Germany. Period prevalence of T2D concordant comorbidities was examined for the periods 2005-2007, 2010-2012 and 2015-2017 in 240,241, 295,868 and 308,134 individuals with T2D respectively. The effect of time period on the number and prevalence of comorbidities was examined by means of (ordered) logistic regression. The age-adjusted predicted probabilities of more severe cardiovascular diseases (CVDs) decreased over the three periods while those of less severe CVDs and other vascular diseases increased significantly in men and women and among all examined age-groups. Predicted probability of having at least one more comorbidity over time also increased significantly among all examined groups. While less and more severe CVDs exhibited different developmental patterns, the results of the study point towards morbidity expansion in T2D. Future studies should focus on mechanisms that contribute to these trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.